Aktienanalyse zu Genprex Inc (GNPX)GNPXGenprex Inc

Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The Company's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. Its oncology drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is developed in combination with approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). GPX-002 is being developed by the Company using the same construct for the treatment of both Type 1 diabetes and Type 2 diabetes. GPX-002 for Type 1 diabetes is designed to work by transforming alpha cells in the pancreas into functional beta-like cells. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Genprex Inc is not a good buy right now due to its significant financial struggles and poor performance metrics. The current price is $2.07, but the stock has seen a staggering year-to-date change of -94.74%, indicating a severe decline in value. Additionally, the RSI is at 41.96, suggesting the stock is nearing oversold territory but still lacks momentum for a rebound. The main risk is highlighted by the company's negative net income, which was -$4,461,895 in Q1 2026, reflecting ongoing financial distress. Given these factors, it is advisable to avoid purchasing this stock at this time.

1 analysts cover GNPX: 1 rate it Buy, 0 Hold and 0 Sell.